Generics: The US Food and Drug Administration (FDA) recently published a new Guidance regarding Prior Approval Supplements (PAS). Read more about FDA´s Guidance for Industry “ANDA Submissions – Prior Approval Supplements Under GDUFA“.
On October 14, 2016, the US Food and Drug Administration (FDA) published a new Guidance regarding Prior Approval Supplements (PAS).
FDA says that “this guidance is intended to assist applicants preparing to submit to FDA prior approval supplements (PASs) and amendments to PASs for abbreviated new drug applications (ANDAs)”.
Specifically, the guidance describes how the Generic Drug User Fee Amendments of 2012 (GDUFA) performance metric goals apply to:
- A PAS subject to the refuse-to-receive (RTR) standards;
- A PAS that requires an inspection;
- A PAS for which an inspection is not required;
- An amendment to a PAS;
- Other PAS-related matters.
GDUFA is designed to speed the delivery of safe and effective generic drugs to the…
View original post 679 more words